Dr. Michael Har-Noy

1
Dr. Michael Har-Noy Reports Remarkable Survival
Data In Breast Cancer Patients
In a preliminary Phase I/II study of AlloStimTM
in patients with various solid metastatic tumors,
Dr. Michael Har-Noy reported encouraging survival
data. Out of the 42 patients studied, Dr.
Michael Har-Noy said that the subset of five
HER2 breast cancer patients had a median
survival of 416 days markedly longer than the
predicted survival of 60 days or less. These
five HER2 patients had high levels of
interleukin 12 an apparent marker for a
positive response. Dr. Michael Har-Noy intends
to conduct a pivotal Phase II/III trial of
AlloStimTM in metastatic breast cancer patients.
2
Dr. Michael Har-Noy Reports Remission of Lung
Cancer In Dog Treated With CRCL Dr. Michael
Har-Noy reports that a 12 year old Great Dane
with bronchoalveolar adenocarcinoma was treated
with a chaperone-rich cell lysate (CRCL) vaccine
processed from the dogs tumor. Dr. Michael
Har-Noy indicates that the expected survival of
the dog was six to 27 days. After treatment, the
dog remained cancer-free for 44 weeks, when a
relapse occurred. The dog was euthanized at
about 50 weeks post-treatment. Dr. Michael
Har-Noy concludes that CRCL vaccine is a safe and
very effective adjuvant treatment for canine
tumors.
3
Dr. Michael Har-Noy Is Conducting A Compassionate
Use Program In Thailand Dr. Michael Har-Noy,
founder and CEO of Immunovative Therapies, Ltd.
is running a Compassionate Use program in
Bangkok, Thailand. Dr. Michael Har-Noy says that
this program is being integrated into Phase I/II
trials of the CRCL-AlloVaxTM compound. The
Compassionate Use program allows patients who
have exhausted other treatment options to benefit
from these unique products. Dr. Michael Har-Noy
will soon be conducting pivotal Phase II/III
trials involving breast and colon cancer
patients. The CRCL-AlloVaxTM product may also
have potential benefit in the treatment of HIV
patients.
4
Dr. Michael Har-Noy Says RECIST Criteria
Inadequately Evaluates Tumor Response To
Immunologic Treatment Dr. Michael Har-Noy says
that conventional RECIST criteria are not
applicable to immunologic cancer treatments.
RECIST criteria dictate that a partial response
to therapy means that a 30 decrease in tumor
size from baseline sum of the longest diameter
must be observed. Dr. Michael Har-Noy says that
after immune treatment, metastatic tumors usually
actually swell secondary to the inflammatory
response and may appear larger on imaging
studies. However, subsequent biopsies of these
enlarged lesions usually show cell death and
fibrosis. Dr. Michael Har-Noy says that as
immunologic treatments become better understood,
more relevant response criteria will be
developed.
5
Thank You
https//www.smore.com/qump-michael-har-noy